Ipamorelin dosage: the microgram numbers people circulate vs. what's actually proven

Type “ipamorelin dosage” into a search bar and the results will hand you a tidy microgram figure as if the matter were closed. It is anything but. Ipamorelin is a research-grade selective growth-hormone secretagogue, and no regulator has approved a human dose for it — there is no product label, no dose-ranging study in healthy adults, none of the machinery that turns a number into a real prescription. Two separate things do exist, and they get blurred together: genuine pharmacology that explains why the popular figures landed where they did, and a tradition of clinic and message-board practice that froze that pharmacology into named injection routines. Our job here is to hold those apart and report on each — this is journalism about how ipamorelin gets dosed, not a sheet of instructions to follow.

The mechanism that sets the dosing logic

None of the dosing logic holds together until you grasp what the molecule actually does. Ipamorelin binds selectively to the ghrelin receptor — the growth-hormone-secretagogue receptor — and when researchers first described it in 1998 the headline was that selectivity: it provoked a brisk release of growth hormone without hauling cortisol and prolactin up with it — the property that earned it the label of the first selective secretagogue of its class.^[1] In plain terms, ipamorelin presses one specific button to fire a clean, brief GH pulse. Everything downstream in the dosing — how much, when, and on an empty stomach — is reasoning about how to make that single pulse land well, not a recipe validated by a trial.

Where the microgram numbers come from: the “saturation dose” idea

The ipamorelin amounts you see over and over — usually a couple of hundred micrograms an injection — descend from one idea in pharmacology, not from any study built to find the right dose. Here is the logic. Feed a secretagogue more and the growth-hormone burst it provokes climbs, but only so far; beyond a certain point the receptors are already maxed out and additional peptide yields almost nothing extra. Practitioners dub the amount at that plateau the “saturation dose,” and scaling it to bodyweight — very roughly a microgram for each kilogram a person carries — produces the per-shot figures that circulate everywhere. As a way to picture a ceilingthe idea holds up fine. What it is not deserves equal candor: it never came from a randomized dose-ranging experiment in healthy volunteers, and a dose tuned to crank a hormone as high as it will go tells you nothing reliable about whether it reshapes a body. Even the surrogate evidence is sparse — in hypogonadal men, secretagogue treatment did push serum IGF-1 upward, proving the axis is listening, yet a moved marker opens the inquiry rather than settling it.^[2]

Why the timing rules look the way they do

Ask about “ipamorelin timing” and you will hear two rules stated as gospel: take it on an empty stomach, and take it at night before sleep. Both descend from the mechanism, not from a clock-controlled experiment. The fasting rule leans on the notion that the glucose-and-insulin bump following any recent food dampens the GH response, so the injection is slotted into a fasted window to keep the burst crisp. The nighttime preference leans on the body’s own largest natural GH surge occurring in early sleep; a before-bed injection is meant to ride with that rhythm rather than against it. The peptide’s short duration of action is the other half of the timing story — because its pulse is brief, when you fire it matters more than it would for a long-acting compound. These are coherent explanations. They are not the same thing as a trial that compared morning versus night dosing for any outcome a buyer cares about, and that distinction is the whole point of this page.

The reported numbers, with caveats attached

With both of those warnings standing, here is the rough outline of what gets traded in clinic and physique settings — reported, not recommended. The powder arrives lyophilized, is reconstituted, and goes in under the skin. Per-shot amounts hover in the low-hundreds-of-micrograms band, which is just the saturation idea written as a number. Frequency runs anywhere from one bedtime injection to two or three across a day in more aggressive setups, and a lot of the routines are cycled — a stretch of weeks on followed by a pause — instead of run forever. Not one of those decisions descends from a controlled trial in people; each is a habit that calcified through being copied. The table below sets every dosing variable beside whatever, if anything, lends it support.

Why ipamorelin is usually stacked with CJC-1295

You almost never find ipamorelin dosed by itself, and the reason is purely mechanical. Ipamorelin delivers a sharp, momentary pulse; CJC-1295 — a GHRH analog engineered to last for days — sustains a steady elevation that lifts the baseline the pituitary fires from. The point of the stack is to drop ipamorelin’s spike atop that raised plateau for a larger combined swing. That blend has its own dosing logic, its own caveats, and its own circulated numbers — and because it is a different question, we keep it on a separate page. For the combined regimen, see our CJC-1295 & ipamorelin dosage breakdown; for whether the pair delivers anything beyond a hormone bump, our ipamorelin & CJC-1295 evidence review is the companion read.

The “bodybuilding” numbers are bigger, not better-supported

The loftier regimens passed around in physique circles — fatter per-shot amounts, more injections in a day, longer unbroken stretches — rest on no firmer ground than the cautious ones. It is the identical empty foundation, merely enlarged. Going beyond the saturation point will not coax much extra growth hormone out of the receptors for free, while it very plausibly enlarges the hazard: hammering the GH/IGF-1 pathway hard and often is precisely the behavior that reopens the unsettled worries around blood-sugar control, water retention, and tissue proliferation. In ipamorelin terms, dialing the dose up mostly purchases extra doubt, not extra evidence.

People who should not be reaching for any dose

Set the number aside entirely — a handful of groups have plain reasons to stay away absent specialist supervision. Anyone living with, or recovered from, cancer, or actively worried about it (the IGF-1 and tissue-growth concerns); anyone with diabetes or shaky glucose tolerance (this pathway can degrade blood-sugar control); those who are pregnant or nursing; minors; and anyone whose existing prescriptions or conditions tangle with hormones or metabolism. For these people, “what dose” has no smaller-and-safer answer — the answer is a clinician’s desk, first.

The honest bottom line

Ipamorelin’s circulating doses are real in the trivial sense that plenty of people inject them, and hollow in the sense that matters: none arrives with the two things a dose is meant to come with — a regulator’s sign-off and a study proving the figure delivers what it promises. The underlying science is sound and even rather elegant: a selective ghrelin-receptor agonist firing a tidy growth-hormone burst, pitched near its saturation ceiling and timed to a fasted, sleeping body. Yet science only accounts for the origin of the numbers; it never certifies them as treatment. If ipamorelin is on your mind, the right next steps are a licensed prescriber, an unflinching look at the evidence, the related cost of the blend, and a comparison with the closest alternative in our sermorelin dosage guide and ipamorelin vs. sermorelin breakdown — not some microgram figure lifted off a forum post. To get the lay of the wider category, browse our vetted peptide-therapy providers and grade each compound in the peptide evidence matrix.